Woodworth, Joshua S. http://orcid.org/0000-0002-0771-9056
Clemmensen, Helena Strand http://orcid.org/0000-0002-2994-3120
Battey, Hannah
Dijkman, Karin http://orcid.org/0000-0002-5395-505X
Lindenstrøm, Thomas http://orcid.org/0000-0002-7162-8124
Laureano, Raquel Salvador
Taplitz, Randy
Morgan, Jeffrey
Aagaard, Claus
Rosenkrands, Ida
Lindestam Arlehamn, Cecilia S. http://orcid.org/0000-0001-7302-8002
Andersen, Peter
Mortensen, Rasmus http://orcid.org/0000-0003-0177-3032
Funding for this research was provided by:
Lundbeckfonden (R249-2017-851)
Det Frie Forskningsråd (DFF – 7025-00106, DFF – 7016-00310)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI135721, 75N9301900067)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 29 April 2021
Accepted: 26 October 2021
First Online: 18 November 2021
Competing interests
: R.M., C.A., and P.A. are co-inventors of a patent covering the use of H107 and derivatives. P.A. and I.R. are also co-inventors of patents covering the use of CAF®01 as an adjuvant. All rights have been assigned to Statens Serum Institut. The remaining authors declare no competing interests.